By regulating the miR-155/Tim-3 pathway, downregulation of NEAT1 can inhibit CD8+ T cell apoptosis and enhance their cytolytic activity against HCC, indicating that NEAT1 is an effective target for improving immunotherapy outcomes (49). Here, HAVCR2 is linked to hepatocellular carcinoma.